Published date: 18 October 2021
Awarded contract - This means that the contract has been awarded to a supplier.
Contract summary
Industry
Analysis services - 71620000
Data analysis services - 72316000
Residential health facilities services - 85144000
Company health services - 85147000
Community health services - 85323000
Location of contract
B4 7WB
Value of contract
£0
Procurement reference
QU496 - AWARD
Published date
18 October 2021
Closing date
3 September 2021
Closing time
12pm
Contract start date
18 October 2021
Contract end date
18 April 2022
Contract type
Service contract
Procedure type
Open procedure
Any interested supplier may submit a tender in response to an opportunity notice.
Contract is suitable for SMEs?
Yes
Contract is suitable for VCSEs?
No
Description
Birmingham City Council requires a supplier for the provision of a Desk Based Report on the Cost Benefit Analysis (CBA) of Genetic Autosomal Recessive Screening. This will be used to inform the action plan of the Birmingham Perinatal and Infant Mortality Strategy. We would like the report to include an estimate of service costs regarding stillbirths, perinatal mortality, infant mortality and lifetime associated with those that survive infancy. Costs can be based on historic service models in addition the estimates for the thresholds of cost effectiveness for each of the above. The costs should be specified for the NHS, social services and the wider costs to society.
For the purposes of developing our Peri-natal and Infant Mortality Strategy, Birmingham City Council (BCC) Public Health requires an evaluation that compares the cost of screening for autosomal recessive conditions with the economic benefits accruing from changes in the prevalence rates of stillbirths, peri-natal and infant mortality and health outcomes. The cost benefits should include the financial savings to services in the health, social care and education sectors and the wider society.
The CBA needs to be based on provision of screening women who are planning a pregnancy and the women and partners who are considered to be at risk from a genetic disorder with X-linked genetic conditions with a panel screening for multiple conditions.
The CBA needs to consider a Genetic Counselling component and the cost considerations for this element.
Your proposal must:
o Describe your methodology for writing this report to include planning, mapping, modelling and reporting
o Provide a breakdown of total costs including key expenditure anticipated to deliver the project
The contract to undertake the CBA of autosomal recessive screening will be for a period of 6 months commencing 13th September 2021.
The Council will be using its free to use e-tendering system (in-tend) for the administration of this procurement process and potential suppliers must register with the system to be able to express an interest. If you wish to express an interest in this opportunity please click on the following link to access https://in-tendhost.co.uk/birminghamcc/ and submit your details to register. You will then be sent details on how to log on which will enable you to download all relevant tender documentation.
If you are unable to register with In-tend or have any questions or problems on how to use this web site please either email us at: cps@birmingham.gov.uk or call CPS Helpdesk on 0121 464 8000.
Your completed tender submission should be returned by noon on 3rd September 2021 via the 'in-tend' system https://in-tendhost.co.uk/birminghamcc
Award information
Awarded date
18 October 2021
Contract start date
18 October 2021
Contract end date
18 April 2022
Total value of contract
£59,950
This contract was awarded to 1 supplier.
UEA Consulting Ltd
Address
The Registry 1.16 Norwich Research Park, Norwich, Norfolk, United Kingdom, NR4 7TJ
Reference
None
Supplier is SME?
No
Supplier is VCSE?
No
About the buyer
Contact name
Manjit Samrai
Address
10 Woodcock Street
Birmingham
West Midlands
B4 7WB
United Kingdom
Telephone
0121 303 0349
Share this notice
Closing: 3 September 2021, 12pm
All content is available under the
